Summary
Global Pharmacokinetics Services Market was valued at USD 993.67 million in 2023 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.12% through 2029. Pharmacokinetics services are a set of scientific and analytical services that play a crucial role in drug development and research. They involve the study of how a drug or therapeutic compound interacts with the human body, including how it is absorbed, distributed, metabolized, and eliminated. Pharmacokinetics services investigate how a drug enters the bloodstream after administration, whether through oral ingestion, injection, inhalation, or other methods. Factors like the drug's chemical properties, formulation, and administration route impact its absorption. Once in the bloodstream, a drug is distributed to various tissues and organs in the body. Pharmacokinetics services analyze the drug's distribution patterns, volume of distribution, and the factors that affect its movement within the body. The body's enzymes often metabolize drugs, transforming them into different chemical compounds. Pharmacokinetics studies assess the drug's metabolism, the role of specific enzymes, and the formation of metabolites, which can be active or inactive.
The growing prevalence of chronic diseases, infectious diseases, and other health conditions necessitates the development of new drugs and therapeutic approaches, driving the demand for pharmacokinetic studies. The need for demonstrating bioequivalence, especially in the generic drug market, drives demand for pharmacokinetic services to prove the equivalence of generic products to their reference drugs. The availability of advanced analytical tools, computational modeling, and bioanalytical techniques has improved the precision and efficiency of pharmacokinetics research. The biotechnology industry's growth, with a focus on innovative therapies like gene therapies and cell-based treatments, requires specialized pharmacokinetics research. As patients often take multiple medications, understanding potential drug-drug interactions is crucial for patient safety. Pharmacokinetic studies are essential for assessing these interactions.
Key Market Drivers
Technological Advancements
High-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC-MS), and gas chromatography-mass spectrometry (GC-MS) have become more sensitive and selective, allowing for the quantification of drugs and metabolites at lower concentrations. Automation and robotics have enabled high-throughput screening of compounds, accelerating the analysis of drug candidates' pharmacokinetic properties. Liquid Chromatography-Mass Spectrometry (LC-MS/MS) has become a standard tool for bioanalysis, offering enhanced sensitivity and selectivity for the quantification of drugs and metabolites in biological matrices. The development of sophisticated pharmacokinetic modeling software allows researchers to simulate and predict the behavior of drugs in the body, helping in the design of clinical trials and dosing regimens.
Computational modeling and simulation are increasingly used to predict pharmacokinetic parameters, which can aid in optimizing drug development processes and reducing the need for extensive in vivo studies. The use of micro dosing (administration of small doses of a drug to humans) combined with highly sensitive analytical techniques has enabled researchers to gather early pharmacokinetic data with minimal risk to study participants. Genomics, proteomics, and metabolomics have provided insights into the interplay between a patient's genetics and drug metabolism, helping to tailor drug therapies to individual patients. Advancements in non-invasive sampling methods, such as dried blood spot (DBS) and micro sampling, have made sample collection more convenient and less invasive for patients. Development of biosensors and wearable devices allows continuous monitoring of drug concentrations in the body, providing real-time pharmacokinetic data.
Specialized technologies, such as ligand-binding assays and LC-MS, are used to study the pharmacokinetics of biologic drugs, including monoclonal antibodies and gene therapies. Microfluidic devices and "organs-on-a-chip" technologies replicate the functions of human organs, enabling the study of drug behavior in specific tissues and organs. The use of nanoparticles and nanocarriers allows for targeted drug delivery, extending drug release, and improving the pharmacokinetics of drugs. Virtual clinical trials use digital twins and modeling to simulate the pharmacokinetics of drugs in various patient populations, reducing the need for physical trials. Secure blockchain technology and advanced data management systems enhance the security and traceability of pharmacokinetic data. AI and machine learning algorithms are employed for data analysis, predicting pharmacokinetic parameters, and optimizing drug development processes. This factor will help in the development of the Global Pharmacokinetics Services Market
Growing Biotech Sector
Biotech companies are at the forefront of developing biologic drugs, such as monoclonal antibodies, vaccines, and gene therapies. These biologics are more complex than small molecules and require specialized pharmacokinetics studies to understand their absorption, distribution, metabolism, and elimination (ADME) profiles. Biologics, including monoclonal antibodies and gene therapies, have distinct pharmacokinetic characteristics compared to small molecules. Understanding their behavior in the body is crucial for dose optimization, efficacy assessment, and safety evaluations. Biologics can trigger immune responses in patients. Pharmacokinetics studies help assess the immunogenicity of biologics and their potential side effects, contributing to the safety evaluation.
Biotech companies often focus on personalized and precision medicine. Pharmacokinetics data is used to customize treatment regimens based on individual patient characteristics, improving treatment outcomes. Biotech firms often develop innovative drug delivery systems, such as nanoparticles and viral vectors. Pharmacokinetics studies are crucial for evaluating the performance of these systems and ensuring effective drug delivery. Gene therapies, which involve the introduction of genetic material into the body, require specialized pharmacokinetics research to assess the persistence and distribution of the introduced genes. Cell-based therapies, including CAR-T cell therapies and stem cell treatments, rely on pharmacokinetics data to understand cell behavior, persistence, and therapeutic effects in patients. Regulatory agencies closely scrutinize the pharmacokinetic data of biologics. Meeting regulatory requirements is essential for obtaining approvals and bringing biologic therapies to market. Pharmacokinetics studies are crucial for the design of clinical trials for biologic therapies, including dosing strategies, endpoints, and patient selection criteria. The biotech sector has experienced rapid growth, and with a robust pipeline of biologic drugs and therapies, the demand for pharmacokinetics services to support research and development remains high. This factor will pace up the demand of the Global Pharmacokinetics Services Market
Increasing Disease Burden
The rise in the incidence of various diseases necessitates the development of new drugs to address unmet medical needs. Pharmacokinetics studies are essential for understanding how these drugs behave in the body, ensuring their safety and efficacy. The increasing disease burden often prompts the pharmaceutical industry and biotechnology companies to innovate and develop new therapeutic approaches, including small molecules, biologics, and gene therapies. Pharmacokinetics services are fundamental in the development and testing of these innovative treatments. The diversity of diseases and patient populations requires treatments to be tailored to specific conditions and individual patient characteristics. Pharmacokinetics data is essential for designing personalized treatment regimens.
The demand for drugs that are more effective and easier for patients to take drives research into optimal drug formulations. Pharmacokinetics studies help determine the most suitable dosage forms and administration routes. Emerging infectious diseases and antimicrobial resistance create an ongoing need for new antimicrobial agents. Pharmacokinetics research is vital for understanding drug behavior in the context of infections. The increasing prevalence of chronic diseases like diabetes, cardiovascular diseases, and cancer necessitates the development of drugs for long-term management. Pharmacokinetics data is used to design sustained-release formulations and assess drug safety in chronic use. Rare and orphan diseases, often neglected in the past, are now receiving more attention. Pharmacokinetics services play a critical role in developing treatments for these conditions. Some diseases require combination therapies, where multiple drugs are used together. Pharmacokinetics studies help determine the optimal dosing and drug interactions in these combinations. Regulatory authorities require extensive pharmacokinetic data to assess the safety and efficacy of new drugs. Compliance with these requirements is vital for market access. The demand for vaccines and preventive measures to combat infectious diseases is increasing. Pharmacokinetics is involved in vaccine development and assessing their effectiveness. This factor will accelerate the demand of the Global Pharmacokinetics Services Market.
Key Market Challenges
Increasing Complexity of Drug Molecules
The pharmaceutical industry is experiencing a shift towards biologics, including monoclonal antibodies, gene therapies, and cell-based treatments. These large and complex molecules have different pharmacokinetic characteristics compared to traditional small molecules. Pharmacokinetics studies for biologics require specialized techniques and expertise. Personalized medicine and precision medicine approaches involve tailoring treatments to individual patients based on their genetic makeup and other factors. This complexity demands a deep understanding of the pharmacokinetics of each patient's unique treatment. Patients often take multiple medications simultaneously. This increases the potential for drug-drug interactions (DDIs) and complex pharmacokinetic profiles that need to be studied to ensure patient safety.
The use of nanoparticles and nanocarriers for drug delivery introduces new complexities. These carriers can alter drug release rates, distribution, and clearance, requiring detailed pharmacokinetic analysis. Complex drug formulations, including sustained-release formulations, liposomal formulations, and drug-loaded nanoparticles, require in-depth pharmacokinetics studies to optimize their performance. Some complex drug molecules, particularly biologics, can trigger immune responses in patients, which adds a layer of complexity to pharmacokinetic assessments and safety evaluations.
Rising Development Costs
The development of new drug molecules, especially biologics and complex therapies, demands substantial resources in terms of research, development, and clinical testing. These high costs create pressure on pharmaceutical companies to make efficient use of their resources, including pharmacokinetics studies. The development of complex drug molecules often requires specialized expertise in areas like biologics, nanotechnology, and advanced drug delivery systems. Acquiring and retaining this expertise can be costly. Meeting stringent regulatory requirements for safety and efficacy necessitates extensive pharmacokinetic studies. This adds to the overall cost of drug development. Many drugs fail in the later stages of clinical trials due to safety or efficacy issues, leading to significant financial losses. Pharmacokinetic data can help identify and address potential issues earlier in the development process, potentially reducing late-stage failures.
Conducting clinical trials, which are an essential component of pharmacokinetic studies, is a major cost driver. Patient recruitment, data collection, and regulatory compliance all contribute to the high cost of clinical trials. Biologics, gene therapies, and other complex molecules require additional investments in manufacturing, quality control, and pharmacokinetics research, adding to development costs. Even the development of biosimilars, which are intended to be cost-effective alternatives to existing biologics, involves significant investments in demonstrating bioequivalence. This requires pharmacokinetic studies that can be expensive. Ensuring an adequate number of patients for clinical trials and retaining them throughout the trial can be cost-prohibitive. Pharmacokinetics studies often require a large patient pool.
Key Market Trends
Outsourcing of Services
Outsourcing pharmacokinetics services can be more cost-effective for pharmaceutical companies, especially for small and medium-sized enterprises (SMEs) with limited budgets. It allows them to access specialized expertise without the need for in-house facilities and staff. Pharmacokinetics is a highly specialized field. Outsourcing provides access to experts and facilities that may not be available in-house, ensuring high-quality research and analysis. Outsourcing allows companies to flexibly allocate resources as needed. They can scale their pharmacokinetics research up or down based on the demands of specific drug development projects. Expert outsourcing partners can expedite the pharmacokinetics research process, which can accelerate drug development and shorten the time to market for new therapies. Outsourcing non-core functions like pharmacokinetics services enables pharmaceutical companies to concentrate on their core competencies, such as drug discovery and clinical trials. Outsourcing enables companies to tap into a global network of contract research organizations (CROs) and service providers with diverse capabilities, enhancing their global reach and access to various markets. Partnering with CROs with established reputations and regulatory compliance can reduce the risk associated with drug development and research.
Segmental Insights
Drug Type Insights
In 2023, the Global Pharmacokinetics Services Market largest share was held by small molecule segment and is predicted to continue expanding over the coming years.Small molecule drugs are used to treat a wide range of diseases and conditions, making them highly versatile and widely applicable. As a result, there's a consistent need for pharmacokinetic studies across various therapeutic areas. The development of generic drugs and biosimilars, often based on small molecules, has grown in significance. Pharmacokinetics studies are crucial for demonstrating bioequivalence and efficacy. Regulatory authorities, such as the FDA, have stringent requirements for the approval of small molecule drugs. Extensive pharmacokinetic data is necessary to demonstrate their safety and efficacy, contributing to the demand for pharmacokinetics services. The high competition in the small molecule drug market necessitates rigorous pharmacokinetic research to ensure that new drug candidates meet the standards for efficacy and safety. Pharmaceutical companies continue to invest heavily in the research and development of small molecule drugs, leading to a consistent demand for pharmacokinetics services throughout the drug development process. The pipeline of small molecule drug candidates remains diverse and active, with new compounds continually entering various stages of development, driving the need for pharmacokinetic studies.
Application Insights
In 2023, the Global Pharmacokinetics Services Market largest share was held by Small medium enterprises (SME) segment and is predicted to continue expanding over the coming years.SMEs are often more agile and flexible in adapting to market demands and trends. This allows them to quickly respond to changing needs in the pharmaceutical industry, such as pharmacokinetics services. SMEs may offer more cost-effective solutions compared to larger, established companies. This cost efficiency can be appealing to pharmaceutical companies, especially startups and emerging biotech firms with limited budgets. Many SMEs specialize in niche areas of pharmacokinetics and offer unique expertise and services that cater to specific needs within drug development and clinical research. SMEs can provide more personalized and hands-on services, establishing closer working relationships with their clients. This can be highly valuable for pharmaceutical companies seeking customized solutions. SMEs often serve as centres of innovation, pushing the boundaries of pharmacokinetics research and developing novel approaches or technologies. The entrepreneurial spirit of SMEs can lead to a culture of continuous improvement and adaptability, which is vital in the fast-evolving pharmaceutical industry.
End-User Insights
In 2023, the Global Pharmacokinetics Services Market largest share was held byAcademic government research institutessegment in the forecast period and is predicted to continue expanding over the coming years.Academic institutions and government research institutes are at the forefront of scientific research and innovation. They often engage in cutting-edge drug development studies and pharmacokinetics research to advance the understanding of drug behaviour in the human body. Many academic and government research institutes have in-house pharmacokinetics experts and state-of-the-art laboratories equipped for conducting pharmacokinetic studies. This expertise and infrastructure make them attractive partners for pharmaceutical companies seeking specialized research capabilities. Collaboration between academia and the pharmaceutical industry is common. Pharmaceutical companies often partner with academic and government research institutions to access their specialized knowledge and resources for drug development and pharmacokinetic studies. Academic and government research institutes frequently receive grants and funding for research projects, including pharmacokinetic studies. This financial support allows them to conduct research in areas of interest without the immediate commercial pressures that private companies face. Academic and government research institutions may have access to diverse patient populations for clinical trials and pharmacokinetic studies, which is crucial for studying drug behavior across different demographics and medical conditions.
Regional Insights
The North America region dominates the Global Pharmacokinetics Services Market in 2023. North America, and the United States in particular, is home to a significant number of pharmaceutical and biotechnology companies. These companies are major users of pharmacokinetics services for drug development, clinical trials, and regulatory approval processes. The United States has a well-established and innovative life sciences and healthcare sector. It invests heavily in research and development, which drives the demand for pharmacokinetics services. The United States has a robust regulatory framework, overseen by the FDA (Food and Drug Administration). Pharmaceutical companies are required to conduct extensive pharmacokinetic studies to meet regulatory requirements for drug safety and efficacy, leading to a high demand for such services. The region has access to cutting-edge analytical and bioanalytical technologies, which are essential for conducting pharmacokinetic studies. This access to advanced tools and methodologies helps maintain North America's competitive advantage. North America boasts a highly skilled and educated workforce, including pharmacokinetics experts, clinical researchers, and data analysts who are crucial for conducting pharmacokinetic studies.
Key Market Players
Evotec AG
Certara, L.P.
Pacific BioLabs
GVK Biosciences Private Limited
Shanghai Medicilon Inc.
Pharmaceutical Product Development, LLC
Charles River Laboratories International, Inc.
PAREXEL International Corporation
Eurofins Scientific SE
Frontage Labs
Report Scope:
In this report, the Global Pharmacokinetics Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Pharmacokinetics Services Market, By Drug Type:
oSmall Molecules
oLarge Molecules
Pharmacokinetics Services Market, By Application:
oSmall and Medium Enterprise
oLarge Enterprise
Pharmacokinetics Services Market, ByEnd-Use:
oBiotechnology Pharmaceutical Companies
oAcademic Government Research Institutes
oOthers
Pharmacokinetics Services Market, By region:
oNorth America
§United States
§Canada
§Mexico
oAsia-Pacific
§China
§India
§South Korea
§Australia
§Japan
oEurope
§Germany
§France
§United Kingdom
§Spain
§Italy
oSouth America
§Brazil
§Argentina
§Colombia
oMiddle East Africa
§South Africa
§Saudi Arabia
§UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Pharmacokinetics Services Market.
Available Customizations:
GlobalPharmacokinetics Services Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
ページTOPに戻る
Table of Contents
1.Product Overview
1.1.Market Definition
1.2.Scope of the Market
1.2.1.Markets Covered
1.2.2.Years Considered for Study
1.2.3.Key Market Segmentations
2.Research Methodology
2.1.Objective of the Study
2.2.Baseline Methodology
2.3.Key Industry Partners
2.4.Major Association and Secondary Sources
2.5.Forecasting Methodology
2.6.Data Triangulation Validation
2.7.Assumptions and Limitations
3.Executive Summary
3.1.Overview of the Market
3.2.Overview of Key Market Segmentations
3.3.Overview of Key Market Players
3.4.Overview of Key Regions/Countries
3.5.Overview of Market Drivers, Challenges, Trends
4.Voice of Customer
5.Global Pharmacokinetics Services Market Outlook
5.1.Market Size Forecast
5.1.1.By Value
5.2.Market Share Forecast
5.2.1.ByDrug Type (Small Molecules, Large Molecules)
5.2.2.By Application (Small and Medium Enterprise, Large Enterprise)
5.2.3.By End-use (Biotechnology Pharmaceutical Companies, Academic Government Research Institutes, others)
5.2.4.By Region
5.2.5.By Company (2023)
5.3.Market Map
6.Asia Pacific Pharmacokinetics Services Market Outlook
6.1.Market Size Forecast
6.1.1.By Value
6.2.Market Share Forecast
6.2.1.By Drug Type
6.2.2.ByApplication
6.2.3.By End-use
6.2.4.By Country
6.3.Asia Pacific: Country Analysis
6.3.1.China Pharmacokinetics Services Market Outlook
6.3.1.1.Market Size Forecast
6.3.1.1.1.By Value
6.3.1.2.Market Share Forecast
6.3.1.2.1.By Drug Type
6.3.1.2.2.By Application
6.3.1.2.3.By End-use
6.3.2.India Pharmacokinetics Services Market Outlook
6.3.2.1.Market Size Forecast
6.3.2.1.1.By Value
6.3.2.2.Market Share Forecast
6.3.2.2.1.By Drug Type
6.3.2.2.2.By Application
6.3.2.2.3.By End-use
6.3.3.Australia Pharmacokinetics Services Market Outlook
6.3.3.1.Market Size Forecast
6.3.3.1.1.By Value
6.3.3.2.Market Share Forecast
6.3.3.2.1.By Drug Type
6.3.3.2.2.By Application
6.3.3.2.3.By End-use
6.3.4.Japan Pharmacokinetics Services Market Outlook
6.3.4.1.Market Size Forecast
6.3.4.1.1.By Value
6.3.4.2.Market Share Forecast
6.3.4.2.1.By Drug Type
6.3.4.2.2.By Application
6.3.4.2.3.By End-use
6.3.5.South Korea Pharmacokinetics Services Market Outlook
6.3.5.1.Market Size Forecast
6.3.5.1.1.By Value
6.3.5.2.Market Share Forecast
6.3.5.2.1.By Drug Type
6.3.5.2.2.By Application
6.3.5.2.3.By End-use
7.Europe Pharmacokinetics Services Market Outlook
7.1.Market Size Forecast
7.1.1.By Value
7.2.Market Share Forecast
7.2.1.By Drug Type
7.2.2.By Application
7.2.3.By End-use
7.2.4.By Country
7.3.Europe: Country Analysis
7.3.1.France Pharmacokinetics Services Market Outlook
7.3.1.1.Market Size Forecast
7.3.1.1.1.By Value
7.3.1.2.Market Share Forecast
7.3.1.2.1.By Drug Type
7.3.1.2.2.By Application
7.3.1.2.3.By End-use
7.3.2.Germany Pharmacokinetics Services Market Outlook
7.3.2.1.Market Size Forecast
7.3.2.1.1.By Value
7.3.2.2.Market Share Forecast
7.3.2.2.1.By Drug Type
7.3.2.2.2.By Application
7.3.2.2.3.By End-use
7.3.3.Spain Pharmacokinetics Services Market Outlook
7.3.3.1.Market Size Forecast
7.3.3.1.1.By Value
7.3.3.2.Market Share Forecast
7.3.3.2.1.By Drug Type
7.3.3.2.2.By Application
7.3.3.2.3.By End-use
7.3.4.Italy Pharmacokinetics Services Market Outlook
7.3.4.1.Market Size Forecast
7.3.4.1.1.By Value
7.3.4.2.Market Share Forecast
7.3.4.2.1.By Drug Type
7.3.4.2.2.By Application
7.3.4.2.3.By End-use
7.3.5.United Kingdom Pharmacokinetics Services Market Outlook
7.3.5.1.Market Size Forecast
7.3.5.1.1.By Value
7.3.5.2.Market Share Forecast
7.3.5.2.1.By Drug Type
7.3.5.2.2.By Application
7.3.5.2.3.By End-use
8.North America Pharmacokinetics Services Market Outlook
8.1.Market Size Forecast
8.1.1.By Value
8.2.Market Share Forecast
8.2.1.By Drug Type
8.2.2.By Application
8.2.3.By End-use
8.2.4.By Country
8.3.North America: Country Analysis
8.3.1.United States Pharmacokinetics Services Market Outlook
8.3.1.1.Market Size Forecast
8.3.1.1.1.By Value
8.3.1.2.Market Share Forecast
8.3.1.2.1.By Drug Type
8.3.1.2.2.By Application
8.3.1.2.3.By End-use
8.3.2.Mexico Pharmacokinetics Services Market Outlook
8.3.2.1.Market Size Forecast
8.3.2.1.1.By Value
8.3.2.2.Market Share Forecast
8.3.2.2.1.By Drug Type
8.3.2.2.2.By Application
8.3.2.2.3.By End-use
8.3.3.Canada Pharmacokinetics Services Market Outlook
8.3.3.1.Market Size Forecast
8.3.3.1.1.By Value
8.3.3.2.Market Share Forecast
8.3.3.2.1.By Drug Type
8.3.3.2.2.By Application
8.3.3.2.3.By End-use
9.South America Pharmacokinetics Services Market Outlook
9.1.Market Size Forecast
9.1.1.By Value
9.2.Market Share Forecast
9.2.1.By Drug Type
9.2.2.By Application
9.2.3.By End-use
9.2.4.By Country
9.3.South America: Country Analysis
9.3.1.Brazil Pharmacokinetics Services Market Outlook
9.3.1.1.Market Size Forecast
9.3.1.1.1.By Value
9.3.1.2.Market Share Forecast
9.3.1.2.1.By Drug Type
9.3.1.2.2.By Application
9.3.1.2.3.By End-use
9.3.2.Argentina Pharmacokinetics Services Market Outlook
9.3.2.1.Market Size Forecast
9.3.2.1.1.By Value
9.3.2.2.Market Share Forecast
9.3.2.2.1.By Drug Type
9.3.2.2.2.By Application
9.3.2.2.3.By End-use
9.3.3.Colombia Pharmacokinetics Services Market Outlook
9.3.3.1.Market Size Forecast
9.3.3.1.1.By Value
9.3.3.2.Market Share Forecast
9.3.3.2.1.By Drug Type
9.3.3.2.2.By Application
9.3.3.2.3.By End-use
10.Middle East and Africa Pharmacokinetics Services Market Outlook
10.1.Market Size Forecast
10.1.1.By Value
10.2.Market Share Forecast
10.2.1.By Drug Type
10.2.2.By Application
10.2.3.By End-use
10.2.4.By Country
10.3.MEA: Country Analysis
10.3.1.South Africa Pharmacokinetics Services Market Outlook
10.3.1.1.Market Size Forecast
10.3.1.1.1.By Value
10.3.1.2.Market Share Forecast
10.3.1.2.1.By Drug Type
10.3.1.2.2.By Application
10.3.1.2.3.By End-use
10.3.2.Saudi Arabia Pharmacokinetics Services Market Outlook
10.3.2.1.Market Size Forecast
10.3.2.1.1.By Value
10.3.2.2.Market Share Forecast
10.3.2.2.1.By Drug Type
10.3.2.2.2.By Application
10.3.2.2.3.By End-use
10.3.3.UAE Pharmacokinetics Services Market Outlook
10.3.3.1.Market Size Forecast
10.3.3.1.1.By Value
10.3.3.2.Market Share Forecast
10.3.3.2.1.By Drug Type
10.3.3.2.2.By Application
10.3.3.2.3.By End-use
11.Market Dynamics
11.1.Drivers
11.2.Challenges
12.Market Trends Developments
12.1.Recent Developments
12.2.Product Launches
12.3.Mergers Acquisitions
13.Porter’s Five Forces Analysis
13.1.Competition in the Industry
13.2.Potential of New Entrants
13.3.Power of Suppliers
13.4.Power of Customers
13.5.Threat of Substitute Product
14.Competitive Landscape
14.1.Evotec AG
14.1.1.Business Overview
14.1.2.Company Snapshot
14.1.3.Products Services
14.1.4.Financials (In case of listed companies)
14.1.5.Recent Developments
14.1.6.Key Personnel Details
14.1.7.SWOT Analysis
14.2.Certara, L.P.
14.3.Pacific BioLabs
14.4.GVK Biosciences Private Limited
14.5.Shanghai Medicilon Inc.
14.6.Pharmaceutical Product Development, LLC
14.7.Charles River Laboratories International, Inc.
14.8.PAREXEL International Corporation
14.9.Eurofins Scientific SE
14.10.Frontage Labs
15.Strategic Recommendations
16. About Us Disclaimer
